Editorial Questionnaire

Your comments are important to us. This form provides you with the opportunity to express your opinions. Our goal is to make CNS Spectrums your source for practical and clinical neuropsychiatric information. By filling out this Questionnaire, you enable us to incorporate your views about our editorial content in future issues. Please fill out this form in its entirety. Thank you.

Name (please print)

Address

City State Zip Code

E-mail Specialty Date

Fax: 212-328-0600. Mail: CNS SPECTRUMS, 333 Hudson Street, 7th Floor, New York, NY 10013

1. On a scale of 1 to 5 (1=Poor, 5=Excellent), please indicate your level of interest and/or satisfaction with the editorial content in this issue.

<table>
<thead>
<tr>
<th>Original Research</th>
<th>Case Reports</th>
<th>Departments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trends in Psychopharmacology</td>
<td>Clinical Updates in Neuropsychiatry</td>
<td>CME</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

2. Which areas of neuropsychiatry would you like us to cover in the future?

3. Please describe your reading pattern for this issue:

- Read cover to cover
- Skipped table of contents
- Read select items of interest
- Skipped text
- Did not read

4. On a scale of 1 to 5 (1=Incomplete, 5=Comprehensive), how would you describe the depth of coverage for this issue?

5. Any other comments about CNS Spectrums' editorial content, design, or overall usefulness?

6. Please indicate your title:

- Neurologist
- Psychiatrist

Please select any of the following complimentary educational materials you would like to receive:

- Amyloid-Based Interventions in Alzheimer's Disease
- Differential Diagnosis of ADHD and Comorbid Conditions
- Incorporating Pharmacogenetics into Clinical Practice: Reality of a New Tool in Psychiatry
- Management of Painful Physical Symptoms Associated with Depression and Mood Disorders
- Recent Advances in the Treatment and Management of Excessive Daytime Sleepiness
- Recognition and Treatment of Depression With or Without Comorbid Anxiety Disorders
- Cholinesterase Inhibitors Across Stages of Dementia and Cognitive Impairments in the Elderly
- Anxiety Disorders and Medical Illness: Risk Factors, Effectiveness Trials, and Quality of Care
- Neuroprotection: A Therapeutic Strategy to Prevent Deterioration Associated with Schizophrenia
- The Role of Modified-Release Formulations in Hypnotic Therapy for Insomnia
- Pain, Stress, and Anxiety: Interrelationships and Treatment Necessities
- Innovative Drug Delivery Systems in the Management of Anxiety
- Long-Term Issues in the Treatment of Sleep Disorders
- The Black Book of Psychotropic Dosing and Monitoring—11th Edition
- The Black Book of Alzheimer's Disease—First Edition
- The Black Book of Insomnia
- The Black Book of ADHD
- The Black Book of OCD
Your comments are important to us. This form provides you with the opportunity to express your opinions. Our goal is to make CNS Spectrums your source for practical and clinical neuropsychiatric information. By filling out this Questionnaire, you enable us to incorporate your views about our editorial content in future issues. Please fill out this form in its entirety. Thank you.

1. On a scale of 1 to 5 (1=Poor, 5=Excellent), please indicate your level of interest and/or satisfaction with the editorial content in this issue.

<table>
<thead>
<tr>
<th>ORIGINAL RESEARCH</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>CASE REPORTS</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

2. Which areas of neuropsychiatry would you like us to cover in the future?

3. Please describe your reading pattern for this issue:

- [ ] Read cover to cover
- [ ] Skimmed table of contents
- [ ] Read select items of interest
- [ ] Skimmed text
- [ ] Did not read

4. On a scale of 1 to 5 (1=Incomplete, 5=Comprehensive), how would you describe the depth of coverage for this issue?

- [ ] 1
- [ ] 2
- [ ] 3
- [ ] 4
- [ ] 5

5. Any other comments about CNS Spectrums’ editorial content, design, or overall usefulness?

6. Please indicate your title:

- [ ] Neurologist
- [ ] Psychiatrist

Please select any of the following complimentary educational materials you would like to receive:

**CME-ACCREDITED CD-ROMs**

- [ ] Amyloid-Based Interventions in Alzheimer’s Disease
- [ ] Differential Diagnosis of ADHD and Comorbid Conditions
- [ ] Incorporating Pharmacogenetics into Clinical Practice: Reality of a New Tool in Psychiatry
- [ ] Management of Painful Physical Symptoms Associated with Depression and Mood Disorders
- [ ] Recent Advances in the Treatment and Management of Excessive Daytime Sleepiness
- [ ] Recognition and Treatment of Depression With or Without Comorbid Anxiety Disorders

**CME-ACCREDITED HYPERCDs**

- [ ] Cholinesterase Inhibitors Across Stages of Dementia and Cognitive Impairments in the Elderly
- [ ] Anxiety Disorders and Medical Illness: Risk Factors, Effectiveness Trials, and Quality of Care
- [ ] Neuroprotection: A Therapeutic Strategy to Prevent Deterioration Associated with Schizophrenia

- [ ] The Role of Modified-Release Formulations in Hypnotic Therapy for Insomnia
- [ ] Pain, Stress, and Anxiety: Interrelationships and Treatment Necessities

**NON-CME-ACCREDITED CD-ROMs AND HYPERCDs**

- [ ] Innovative Drug Delivery Systems in the Management of Anxiety
- [ ] Long-Term Issues in the Treatment of Sleep Disorders

**CLINICAL POCKET REFERENCE GUIDES**

- [ ] The Black Book of Psychotropic Dosing and Monitoring—11th Edition
- [ ] The Black Book of Alzheimer’s Disease—First Edition
- [ ] The Black Book of Insomnia
- [ ] The Black Book of ADHD
- [ ] The Black Book of OCD
Alzheimer's Disease Summit
Translating Research Advances Into Clinical Practice

Save the Date:
Saturday, May 3, 2008 • The Park Hyatt • Washington, DC
8:00 a.m. – 7:00 p.m.

Program Chairs:
Jeffrey L. Cummings, MD, and Pierre N. Tariot, MD

Educational Sessions Include:

• Advances in Clinical Assessment
• Advances in Neuroimaging and Biomarkers
• Panel Discussion including Russell Katz, MD, Director of Neurology Products, FDA
• Current Alzheimer Therapy: Best Practices
• The Future of Alzheimer Therapeutics

For complete ADS program and registration information, please visit www.adsummit2008.com

For questions regarding the ADS, please e-mail sw@mblcommunications.com

Primary Psychiatry • CNS Spectrum • Psychiatry Weekly
A Global Commitment to Advancing CNS Science, Clinical Practice, and Evidence-Based Medicine
3rd INTERNATIONAL CONGRESS ON
WOMEN'S MENTAL HEALTH
MELBOURNE AUSTRALIA
17 - 20 March 2008

Opening Minds
to Women's Mental Health

Visit our Congress website at

INTERNATIONAL ASSOCIATION FOR
WOMEN'S MENTAL HEALTH
www.iawmh.org

https://doi.org/10.1017/S1092852900016217 Published online by Cambridge University Press
We think they’ll be great together. At Vanda, we’re using pharmacogenetics to match promising molecules to the right patients. So selecting the right medicine will be easier, thanks to our more personal approach.

To learn more, visit www.vandapharma.com.
A GOLDEN OPPORTUNITY...
EXCLUSIVE OFFER:
E-PRESCRIBING PLUS PRACTICE-BASED MEDICATION EFFECTIVENESS TRACKING

Go beyond the current benefits of e-prescribing to enhance your practice with in-depth medication effectiveness knowledge. Prescribers of psychiatric medications are cordially invited to join the powerful Akario CNS Medication Monitoring Network™ today.

Benefits of Akario membership:

• **COMPLIMENTARY** annual license to DrFirst’s award-winning SureScripts GoldRx Certified Rcopia™ (visit www.drfirst.com for more information) electronic prescription management system

• Plus, **ADVANCED** prescriber-based medication effectiveness reporting features available only to this exclusive network of healthcare professionals

• On-demand, patient-specific drug efficacy and tolerability reports that will enable you to evaluate and track medication effectiveness for all of your patients

• De-identified Akario network reports that allow you to compare treatment effectiveness with your patients versus that of the entire prescriber network

• In-depth data on how CNS drugs are being used in clinical practice

• Obtain real-time clinical decision support tools to avoid drug/drug interactions, drug allergies, and adverse events

• Help your patients save $$$ with formulary compliance features

• Streamline your office workflow and increase productivity by:
  – Avoiding pharmacy callbacks for renewal requests
  – Renewing multiple patients’ medications with one click

• Access patient medication history across healthcare providers

To see if you qualify to participate in the network and learn more about joining this groundbreaking initiative, contact us at **info@akario.com** or call **1-212-328-0800 x211**

Free offer is only available to prescribing psychiatric and mental health practitioners with high speed Internet access (cable, DSL, or T1). Akario reserves the right to cancel memberships if the provider/member is not an active network participant.